{
    "clinical_study": {
        "@rank": "154768", 
        "arm_group": {
            "arm_group_label": "Ancillary-Correlative (heavy metal and neurotoxicity)", 
            "description": "Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment."
        }, 
        "biospec_descr": {
            "textblock": "Whole blood"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This research trial studies heavy metal exposure in predicting peripheral neuropathy in\n      patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood\n      and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy\n      may help doctors find out whether side effects from chemotherapy are related to heavy metal\n      exposure."
        }, 
        "brief_title": "Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy", 
        "condition": [
            "Male Breast Cancer", 
            "Neurotoxicity", 
            "Peripheral Neuropathy", 
            "Stage IA Breast Cancer", 
            "Stage IB Breast Cancer", 
            "Stage II Breast Cancer", 
            "Stage IIIA Breast Cancer", 
            "Stage IIIB Breast Cancer", 
            "Stage IIIC Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Peripheral Nervous System Diseases", 
                "Neurotoxicity Syndromes", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To describe the correlation, if any, of specific heavy metals with high grade symptoms of\n      peripheral neuropathy, defined as grade >= 3 peripheral neuropathy, (utilizing the Common\n      Terminology Criterial for Adverse Events [CTCAE] version [v.] 4.0) in a cohort of breast\n      cancer patients undergoing (neo)adjuvant taxane chemotherapy.\n\n      SECONDARY OBJECTIVES:\n\n      I. To characterize the range of specific heavy metals in a cohort of breast cancer patients\n      undergoing (neo)adjuvant chemotherapy treatment.\n\n      II. To evaluate the reproducibility of sera and urine testing of heavy metal levels by\n      inductively coupled plasma mass spectrometry (ICP-MS) testing in a cohort of breast cancer\n      patients undergoing (neo)adjuvant taxane chemotherapy.\n\n      OUTLINE:\n\n      Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at\n      baseline and at the completion of treatment. Patients also complete neurotoxicity assessment\n      questionnaire at baseline and at the completion of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed invasive mammary carcinoma; any\n             histologic sub-type allowed\n\n          -  Patients must be diagnosed with stage I, II or III breast cancer\n\n          -  Patients must be undergoing treatment with an adjuvant or neoadjuvant cytotoxic\n             chemotherapy that includes a taxane, specifically paclitaxel, nab-paclitaxel\n             (Abraxane), or docetaxel\n\n          -  Patients may have received prior endocrine and/or radiation therapy\n\n          -  Patients must have the ability to understand and the willingness to sign a written\n             informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have been previously treated with cytotoxic chemotherapy\n\n          -  Patients with pre-existing peripheral neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Cancer Center"
            }
        }, 
        "enrollment": {
            "#text": "113", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982591", 
            "org_study_id": "ERP-BR-059", 
            "secondary_id": [
                "NCI-2013-01957", 
                "IRB#10-039", 
                "BR-059", 
                "ERP-BR-059", 
                "P30CA006927"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Ancillary-Correlative (heavy metal and neurotoxicity)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Ancillary-Correlative (heavy metal and neurotoxicity)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dabrowm@mlhs.org", 
                    "last_name": "Michael B. Dabrow", 
                    "phone": "610-648-1637"
                }, 
                "facility": {
                    "address": {
                        "city": "Paoli", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19301"
                    }, 
                    "name": "Paoli Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael B. Dabrow", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lori.goldstein@fccc.edu", 
                    "last_name": "Lori J. Goldstein", 
                    "phone": "215-728-2689"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lori J. Goldstein", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy", 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Lori Goldstein", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Heavy metal levels will be characterized in participants being treated at participating sites. Means and variances and ranges of these levels will be tabulated.", 
                "measure": "Level of heavy metal in blood and urine", 
                "safety_issue": "No", 
                "time_frame": "The levels will be measured on a blood and urine sample obtained on the first day of chemotherapy, which is considered the first day of the study. The actual laboratory processing of the samples will occur in batches throughout the duration of the study."
            }, 
            {
                "description": "Neurotoxicity grade during chemotherapy will be obtained from the medical record and study doctor's notes. The maximum grade during the course of chemotherapy will be recorded. Frequencies of toxicities will be tabulated.", 
                "measure": "Incidence of high grade neurotoxicity, defined as grade >= 3 peripheral neuropathy, graded according to CTCAE v. 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Last day of chemotherapy approx.4-6 months from initiation, depending on chemotherapy regimen. Neurotoxicity grade will be assessed intermittently during course of therapy, with note of maximum grade made by clinician."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982591"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fox Chase Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fox Chase Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}